Immuneering (IMRX) Cash from Investing Activities (2020 - 2026)

Immuneering's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$63.1 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 704995.3% year-over-year to -$63.1 million in Q1 2026; TTM through Mar 2026 was -$151.8 million, a 3115.8% decrease from a year earlier, with the FY2025 full-year figure at -$88.7 million, down 435.69% from the prior year.
• Cash from Investing Activities improved to -$63.1 million in Q1 2026 per IMRX's latest filing, from -$88.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $22.2 million in Q2 2022 and bottomed at -$88.7 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is $3.1 million (2023), against an average of -$4.5 million.
• Across the five-year window, Cash from Investing Activities jumped 111852.97% in 2022 and tumbled 704995.3% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at $8.2 million in 2022, then tumbled by 61.57% to $3.1 million in 2023, then jumped by 75.26% to $5.5 million in 2024, then slumped by 1715.84% to -$88.7 million in 2025, then advanced by 28.91% to -$63.1 million in 2026.
• Per Business Quant, the three latest IMRX Cash from Investing Activities figures stand at -$63.1 million (Q1 2026), -$88.7 million (Q4 2025), and -$7255.0 (Q3 2025).